Bevacizumab, a monoclonal antibody targeting VEGF, has demonstrated the ability to extend progression-free survival (PFS) and overall survival (OS) in clinical trials and has been approved for ovarian cancer treatment (17, 18). This evidence concerns the gene VEGFA and ovarian carcinoma.